{"filing":{"accession_number":"0001438533-26-000068","cik":"0001438533","ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"tvtx-20260921.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/tvtx-20260921.htm"},"events":[{"id":33985,"run_id":31285,"accession_number":"0001438533-26-000068","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Bradley L. Campbell has been appointed as President and Chief Executive Officer and Board member effective December 1, 2026, succeeding Eric Dube. While the filing also discloses Dube's departure and compensatory arrangements, the principal disclosed action centers on Campbell's appointment to the top executive role, supported by detailed background, employment agreement terms, and equity awards totaling approximately $16.5 million in initial grants plus a $3.75 million performance-based award.","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37592,"accession_number":"0001438533-26-000068","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Bradley L. Campbell has been appointed as President and Chief Executive Officer and Board member effective December 1, 2026, succeeding Eric Dube. While the filing also discloses Dube's departure and compensatory arrangements, the principal disclosed action centers on Campbell's appointment to the top executive role, supported by detailed background, employment agreement terms, and equity awards totaling approximately $16.5 million in initial grants plus a $3.75 million performance-based award.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:12:57.264143+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37592,"accession_number":"0001438533-26-000068","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Bradley L. Campbell has been appointed as President and Chief Executive Officer and Board member effective December 1, 2026, succeeding Eric Dube. While the filing also discloses Dube's departure and compensatory arrangements, the principal disclosed action centers on Campbell's appointment to the top executive role, supported by detailed background, employment agreement terms, and equity awards totaling approximately $16.5 million in initial grants plus a $3.75 million performance-based award.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:12:57.264143+00:00","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-09-21"}]}